{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:25:16Z","timestamp":1780331116857,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1\u2013014"],"award-info":[{"award-number":["2021-I2M-1\u2013014"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["CICAMS-MOTRP2022004"],"award-info":[{"award-number":["CICAMS-MOTRP2022004"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.breast.2023.103581","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T23:26:21Z","timestamp":1695165981000},"page":"103581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8389-879X","authenticated-orcid":false,"given":"Maiyue","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongnan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10286","key":"10.1016\/j.breast.2023.103581_bib1","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.breast.2023.103581_bib2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10549-021-06216-5","article-title":"Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (MNH) in HER2-positive metastatic breast cancer: a phase II trial","volume":"188","author":"Wang","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2023.103581_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-Targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.breast.2023.103581_bib4","first-page":"51","article-title":"Discovery and Development of pyrotinib: a Novel irreversible EGFR\/HER2 dual tyrosine kinase inhibitor with Favorable safety profiles for the treatment of breast cancer","volume":"110","author":"Li","year":"2017","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"issue":"29","key":"10.1016\/j.breast.2023.103581_bib5","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.19.00108","article-title":"Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, Anthracyclines, and\/or trastuzumab: a randomized, phase II study","volume":"37","author":"Ma","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.breast.2023.103581_bib6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","article-title":"Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Xu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.breast.2023.103581_bib7","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.3390\/cancers13092236","article-title":"Metronomic chemotherapy","volume":"13","author":"Cazzaniga","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.breast.2023.103581_bib8","first-page":"2103","article-title":"Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer","volume":"9","author":"Xuhong","year":"2019","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.breast.2023.103581_bib9","unstructured":"Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/28498781\/(accessed 2022-04-27)."},{"issue":"23","key":"10.1016\/j.breast.2023.103581_bib10","doi-asserted-by":"crossref","first-page":"8352","DOI":"10.1002\/cam4.4335","article-title":"Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: a Real-world Retrospective study","volume":"10","author":"Li","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.breast.2023.103581_bib11","article-title":"Pyrotinib in the treatment of women with HER2-positive advanced breast cancer: a multicenter, prospective, Real-world study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.breast.2023.103581_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10549-022-06770-6","article-title":"Pyrotinib combined with trastuzumab and chemotherapy for the treatment of Human Epidermal growth Factor receptor 2-positive metastatic breast cancer: a single-arm Exploratory phase II trial","volume":"197","author":"Xie","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2023.103581_bib13","article-title":"Pyrotinib combined with vinorelbine in HER2-positive metastatic breast cancer: a multicenter Retrospective study","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.breast.2023.103581_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13546","article-title":"Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for stage I\u2013III HER2-positive breast cancer: a phase II clinical trial","volume":"25","author":"Xuhong","year":"2020","journal-title":"Oncol"},{"issue":"1\u20132","key":"10.1016\/j.breast.2023.103581_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000520236","article-title":"Metronomic chemotherapy for metastatic breast cancer","volume":"45","author":"Krajnak","year":"2022","journal-title":"Oncol Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2023.103581_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2011.06.040","article-title":"Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in Heavily Pretreated patients with metastatic breast cancer","volume":"48","author":"Fedele","year":"2012","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2023.103581_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.hemonc.2014.11.003","article-title":"Metronomic capecitabine as Extended adjuvant chemotherapy in women with triple negative breast cancer","volume":"8","author":"Alagizy","year":"2015","journal-title":"Hematol. Oncol. Stem Cell Ther."}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762300557X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762300557X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:46:52Z","timestamp":1760777212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762300557X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":17,"alternative-id":["S096097762300557X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2023.103581","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2023.103581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103581"}}